A quality improvement approach to rheumatoid arthritis management with biologic disease-modifying antirheumatic drugs: Assessing variability in a treatment pathway

Amish J. Dave; Heather O. Tory; J. Adebukola Awosogba; Jonathan S. Coblyn; Bonnie Bermas; Daniel H. Solomon; Sonali P. Desai

doi:10.1097/RHU.0000000000000474

A quality improvement approach to rheumatoid arthritis management with biologic disease-modifying antirheumatic drugs: Assessing variability in a treatment pathway

Amish J. Dave, Heather O. Tory, J. Adebukola Awosogba, Jonathan S. Coblyn, Bonnie Bermas, Daniel H. Solomon, Sonali P. Desai

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	66-69
Number of pages	4
Journal	Journal of Clinical Rheumatology
Volume	23
Issue number	1
DOIs	https://doi.org/10.1097/RHU.0000000000000474
State	Published - 2017

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1097/RHU.0000000000000474

Cite this

@article{2b47d80a71904dd08fccbce6965b07f3,

title = "A quality improvement approach to rheumatoid arthritis management with biologic disease-modifying antirheumatic drugs: Assessing variability in a treatment pathway",

author = "Dave, {Amish J.} and Tory, {Heather O.} and Awosogba, {J. Adebukola} and Coblyn, {Jonathan S.} and Bonnie Bermas and Solomon, {Daniel H.} and Desai, {Sonali P.}",

note = "Funding Information: A.J.D. and H.O.T. are co-first authors. H.O.T. received salary support for this work from the Risk Management Foundation of the Harvard Medical Institutions, Inc. (CRICO). D.H.S.'s work on this project was supported by the National Institutes of Health (K24 AR055989 and P60 AR 047782). D.H.S. also receives salary support from research grants to his institution from Amgen, Pfizer, Lilly, Genentech, and Corrona. The authors have no other potential conflicts of interest relevant to this manuscript and have not received support or benefits from commercial sources for the work reported.",

year = "2017",

doi = "10.1097/RHU.0000000000000474",

language = "English (US)",

volume = "23",

pages = "66--69",

journal = "Journal of Clinical Rheumatology",

issn = "1076-1608",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - A quality improvement approach to rheumatoid arthritis management with biologic disease-modifying antirheumatic drugs

T2 - Assessing variability in a treatment pathway

AU - Dave, Amish J.

AU - Tory, Heather O.

AU - Awosogba, J. Adebukola

AU - Coblyn, Jonathan S.

AU - Bermas, Bonnie

AU - Solomon, Daniel H.

AU - Desai, Sonali P.

N1 - Funding Information: A.J.D. and H.O.T. are co-first authors. H.O.T. received salary support for this work from the Risk Management Foundation of the Harvard Medical Institutions, Inc. (CRICO). D.H.S.'s work on this project was supported by the National Institutes of Health (K24 AR055989 and P60 AR 047782). D.H.S. also receives salary support from research grants to his institution from Amgen, Pfizer, Lilly, Genentech, and Corrona. The authors have no other potential conflicts of interest relevant to this manuscript and have not received support or benefits from commercial sources for the work reported.

PY - 2017

Y1 - 2017

UR - http://www.scopus.com/inward/record.url?scp=85007376547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007376547&partnerID=8YFLogxK

U2 - 10.1097/RHU.0000000000000474

DO - 10.1097/RHU.0000000000000474

M3 - Letter

C2 - 28002163

AN - SCOPUS:85007376547

SN - 1076-1608

VL - 23

SP - 66

EP - 69

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

IS - 1

ER -

A quality improvement approach to rheumatoid arthritis management with biologic disease-modifying antirheumatic drugs: Assessing variability in a treatment pathway

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this